Erratum (DOI:10.1053/j.ajkd.2008.09.006);Ferumoxytol as a New, Safer, Easier-to-Administer Intravenous Iron: Yes or No?

American Journal of Kidney Diseases

Volumn 52, Issue 5, 2008, Pages 826-829

  Auerbach, Michael ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; INJECTAFER; IRON; IRON DEXTRAN; IRON SALT; PLACEBO; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ENZYMURIA; HUMAN; INJECTION SITE REACTION; NONHUMAN; PROTEINURIA;

EID: 54149084580     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.04.013     Document Type: Erratum

References (25)

1. Watson Pharmaceuticals, Inc: INFeD Prescribing Information (2006), Watson Pharmaceuticals, Inc, Morristown, NJ
2. American Regent, Inc: DexFerrum Prescribing Information (2001), American Regent, Inc, Shirley, NY
3. Watson Pharmaceuticals, Inc: Ferrlecit Prescribing Information (2004), Watson Pharmaceuticals, Inc, Morristown, NJ
4. American Regent, Inc: Venofer Prescribing Information (2005), American Regent, Inc, Shirley, NY
5. Landry R., Jacobs P.M., Davis R., et al. Pharmacokinetic study of Ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 25 (2005) 400-410
6. Manley H.J., and McClaran M.L. Determination of VIT 45 (IND#63,243 - American Regent) removal by closed loop in vitro hemodialysis system. Int J Artif Organs 29 (2006) 1062-1066
7. FDA Advisory Committee Briefing Document, Drug Safety and Risk Management Committee, February 1, 2008. http://www.fda.gov/ohrms/dockets/AC/08/briefing/2008-4337b1-01-FDA.pdf Accessed August 27, 2008
8. Singh A., Patel T., Hertel J., et al. Safety of Ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 52 (2008) 907-915
9. Chertow G.M., Mason P.D., Vaage-Nilsen O., and Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21 (2006) 378-382
10. Rodgers G.M., Auerbach M., Cella D., et al. High-molecular weight iron dextran: a wolf in sheep's clothing?. J Am Soc Nephrol 19 (2008) 833-834
11. Zager R.A., Johnson A.C.M., Hanson S.Y., and Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40 (2002) 90-103
12. Zager R.A., Johnson A.C.M., and Hanson S.Y. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 66 (2004) 144-156
13. Agarwal R.A., Vasavada N., Sachs N.G., and Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 (2004) 2279-2289
14. Leehey D.J., Palubiak D.J., Chebrolu S., and Agarwal R. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant 20 (2005) 135-140
15. Agarwal R., Rizkala A.R., Kaskas M.O., Minasian R., and Trout J.R. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72 (2007) 638-642
16. Agarwal R. On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. Am J Physiol Renal Physiol 288 (2005) F265-F271
17. Pai A.B., Boyd A.V., McQuade C.R., et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 27 (2007) 343-350
18. Auerbach M., and Al Talib K.A. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 73 (2008) 528-530
19. Auerbach M., and Rodgers G.M. Intravenous iron. N Engl J Med 357 (2007) 93-94
20. Monieum K.A., and Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: a comparison of preparations. Transfusion Altern Transfusion Med 9 (2007) 37-42
21. Sav T., Tokgoz B., and Sipahioglu M.H. Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran?. Ren Fail 29 (2007) 423-426
22. Fishbane S., Ungureanu V.D., Maesake J.K., Kaupke C.J., Lim V., and Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28 (1996) 528-534
23. Asero R., Tedeschi A., Riboldi P., Grafini S., Bonanni E., and Cugno M. Coagulation cascade and fibrinolysis in patients with multiple-drug allergy syndrome. Ann Allergy Asthma Immunol 100 (2008) 44-48
24. Coyne D.W., Adkinson Jr. F.N., Nissenson A.R., et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 63 (2003) 217-224
25. Auerbach M., Ballard H., and Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 369 (2007) 1502-1504